Good progress!
According to clinicaltrials.gov, up to 32 patients will be enrolled. So if 20 more patients will be dosed during the dose expansion cohort per today's ASX announcement, that means 12 patients have already been dosed - with no major side effects.
We should get some prelim data by the end of the year. This may coincide with the ASH conference (the premier event in malignant and non-malignant hematology) in the US in December. Given the strong efficacy signals and two complete responses in the Case Western CORE NK AML Trial using...this bodes well for this trial!! (albeit different eligibility criteria and treatment regime)
https://clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1
Good progress!According to clinicaltrials.gov, up to 32 patients...
Add to My Watchlist
What is My Watchlist?
